You are here

cancer

Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer

Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer

Globe Newswire

Larkspur Biosciences

Flag link:

LabGenius utilizing machine learning to ‘transform’ cancer treatment

LabGenius utilizing machine learning to ‘transform’ cancer treatment

Biopharma Reporter

machine learning

antibody discovery

artificial intelligence

Flag link:

Drug Shortages Near an All-Time High, Leading to Rationing

Drug Shortages Near an All-Time High, Leading to Rationing

NY Times, NY

Flag link:

Takeda puts $510M on the line to expand KSQ cancer collaboration

Takeda puts $510M on the line to expand KSQ cancer collaboration

Fierce Biotech

KSQ Therapeutics

Flag link:

Why Shares of Cassava Sciences Jumped Last Week

Why Shares of Cassava Sciences Jumped Last Week

Motley Fool

Cassava Sciences

Flag link:

FibroGen grabs an option to buy cancer drug startup Fortis

FibroGen grabs an option to buy cancer drug startup Fortis

BioPharma Dive

Fortis Therapeutics

Flag link:

Cash-rich BioNTech broadens scope as COVID shot sales slide

Cash-rich BioNTech broadens scope as COVID shot sales slide

Yahoo/Reuters

Flag link:

Experts spar over the benefits of liquid biopsy to catch cancer

Experts spar over the benefits of liquid biopsy to catch cancer

Stat

Flag link:

Incyte whittles down pipeline, scrapping 6 R&D programs

Incyte whittles down pipeline, scrapping 6 R&D programs

Fierce Biotech

Flag link:

Novartis plant cleared to produce in-demand cancer drug

Novartis plant cleared to produce in-demand cancer drug

BioPharma Dive

drug manufacturing

radiopharmaceuticals

Flag link:

BMS signs ADC development deal with Munich-based biotech worth more than $1B

BMS signs ADC development deal with Munich-based biotech worth more than $1B

Medical Marketing and Media

Bristol Myers Squibb

antibody-drug conjugate

Flag link:

Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

Biopharma Reporter

Moderna Therapeutics

cancer vaccines

clinical trials

Flag link:

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

Medivir presents new data at AACR showing significantly improved antitumor efficacy in non-clinical tumor models with fostrox in triple combination

BioSpace

Flag link:

Argenx, Genmab pool expertise on antibody discovery, joining forces to expand into new therapeutic areas

Argenx, Genmab pool expertise on antibody discovery, joining forces to expand into new therapeutic areas

Fierce Biotech

antibody discovery

Flag link:

TORL BioTherapeutics launches with $158M to target cancer

TORL BioTherapeutics launches with $158M to target cancer

Labiotech.eu

TORL BioTherapeutics

Flag link:

Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment

Function Oncology raises $28M to use CRISPR to tailor cancer diagnosis and treatment

BioPharma Dive

Function Oncology

Flag link:

GSK outlines deal to send cell therapies back to Adaptimmune

GSK outlines deal to send cell therapies back to Adaptimmune

BioPharma Dive

Adaptimmune Therapeutics

Flag link:

Moderna Stock Yo-Yoes Winning A Key Battle For Its Cancer Vaccine

Moderna Stock Yo-Yoes Winning A Key Battle For Its Cancer Vaccine

Investors Business Daily

Moderna Therapeutics

Flag link:

Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail

Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail

BioSpace

clinical trials

colorectal cancer

Flag link:

AbbVie removes two approvals for blood cancer drug Imbruvica

AbbVie removes two approvals for blood cancer drug Imbruvica

BioPharma Dive

Flag link:

Pages